Hypothalamic anorexigenic signaling pathways (leptin, amylin, …
2023年1月15日 · Our results support the notion of semaglutide-activated anorexigenic signaling in DIO mice by restoring leptin, amylin, and POMC pathways. Furthermore, the beneficial anorectic effects of semaglutide exceeded the weight loss and the reduction of energy intake since the pair-feed group did not show the same magnitude of alterations.
amylin agonist ZP8396 and the GLP-1 agonist semaglutide(SEMA) •To assess the effect of ZP8396 and SEMA alone and in combination on body weight and food intake in diet-induced obese (DIO) rats • Co-formulations of anti-obesity drugs hold great potential for weight management while maintaining a positive safety and tolerability profile.
1406-P: ZP8396, a Novel Amylin Analogue, Induces Weight Loss in DIO …
The ability of ZP8396 (1, 3, and 15 nmol/kg, s.c., every 2nd day for 21 days) to reduce BW was tested in diet-induced obese (DIO) rats. ZP8396, at concentration supporting pharmacological relevant human doses, is stable in an aqueous formulation at neutral pH and shows no aggregation potential.
213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin …
2022年6月1日 · Amylin improves glucose homeostasis through at least three distinct mechanisms of action, including prevention of the postprandial rise in plasma glucagon, slowing of gastric emptying, and increased satiety, leading to decreased caloric intake and potential weight loss.
Identification and utility exploration of a highly potent and long ...
2024年7月1日 · bGLP-10 exhibits superior hypoglycemic and food intake inhibition effects over semaglutide. bGLP-10 shows broad utility in GLP-1 and amylin combination therapy. bGLP-10 combined with cagrilintide showed notable treatment effects in DIO mice.
Preclinical Weight Loss Efficacy of AM833 in Combination With ...
2021年5月3日 · Here, we present the combined effect of AM833 and semaglutide on weight loss in rodent models of obesity. Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Hypothalamic anorexigenic signaling pathways (leptin, amylin, …
2022年12月1日 · Key findings DIO mice showed increased energy intake and BW linked to leptin and amylin resistance. Semaglutide improved leptin sensitivity and anorexigenic signaling but lessened orexigenic...
Hepatoprotective effects of semaglutide, lanifibranor and dietary ...
The Gubra-Amylin NASH (GAN) diet-induced obese (DIO) mouse demonstrate clinical translatability with respect to disease etiology and hallmarks of NASH. This study aimed to evaluate disease progression and responsiveness to …
Semaglutide lowers body weight in rodents via distributed neural …
2020年3月26日 · Diet-induced obese (DIO) mice and rats fed a high-fat diet received semaglutide, administered subchronically, and the effects on food intake and BW were evaluated. In a 3-week study in DIO mice, semaglutide dose-dependently reduced BW and suppressed food intake.
Zealand Pharma Announces Presentation of Preclinical Data
2021年11月1日 · Preclinical data showed anti-obesity effects of amylin analogue ZP8396 in in vivo models, with up to 20% weight loss when combined with GLP1 analogue semaglutide. In a Phase 1b dose escalation...